Biotech Values

[DewDiligence]

If the USPTO had simply backdated MDCO’s application for statutory extension of the Angiomax patent by one day, there would have been nothing for MDCO to litigate. Of course, bureaucrats would not actually do that because someone else—for instance, a MDCO competitor—might find out about the missed deadline and then they might sue the PTO. Hence my prior post in this thread was more of a rant than a serious indictment of the PTO. Nevertheless, as a taxpayer, I do have a sense that my money was wasted by all these machinations.